Cisatracurium Besylate and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Cisatracurium Besylate and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: cisatracurium
Brand name: Nimbex
Synonyms: Cisatracurium
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cisatracurium Besylate-Insulin degludec
- Cisatracurium Besylate-Insulin Degludec (U-100) Prefilled Pens
- Cisatracurium Besylate-Insulin Degludec (U-100) Vials
- Cisatracurium Besylate-Insulin Degludec (U-200) Prefilled Pens
- Cisatracurium Besylate-Insulin degludec and liraglutide
- Cisatracurium Besylate-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Cisatracurium Besylate Injection
- Insulin aspart, recombinant Subcutaneous-Cisatracurium besylate Intravenous
- Insulin aspart, recombinant Subcutaneous-Cisplatin
- Insulin aspart, recombinant Subcutaneous-Cisplatin Intravenous
- Insulin aspart, recombinant Subcutaneous-Citalopram
- Insulin aspart, recombinant Subcutaneous-Citalopram Capsules